WallStSmart

Alignment Healthcare LLC (ALHC)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 1333% more annual revenue ($56.58B vs $3.95B). NVS leads profitability with a 23.9% profit margin vs -0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

ALHC

Hold

37

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 6.7Quality: 6.8
Piotroski: 5/9Altman Z: 3.87

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALHCUndervalued (+63.3%)

Margin of Safety

+63.3%

Fair Value

$55.62

Current Price

$22.54

$33.08 discount

UndervaluedFair: $55.62Overvalued
NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALHC2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
44.4%10/10

Revenue surging 44.4% year-over-year

Altman Z-ScoreHealth
3.8710/10

Safe zone — low bankruptcy risk

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

ALHC4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
25.6x2/10

Trading at 25.6x book value

Return on EquityProfitability
-0.7%2/10

ROE of -0.7% — below average capital efficiency

Free Cash FlowQuality
$-66.63M2/10

Negative free cash flow — burning cash

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ALHC

The strongest argument for ALHC centers on Revenue Growth, Altman Z-Score. Revenue growth of 44.4% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : ALHC

The primary concerns for ALHC are EPS Growth, Price/Book, Return on Equity.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

ALHC profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.

ALHC carries more volatility with a beta of 1.20 — expect wider price swings.

ALHC is growing revenue faster at 44.4% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 37/100), backed by strong 23.9% margins. ALHC offers better value entry with a 63.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alignment Healthcare LLC

HEALTHCARE · HEALTHCARE PLANS · USA

Alignment Healthcare, Inc. provides a consumer-centric platform that provides personalized healthcare to seniors in the United States. The company is headquartered in Orange, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?